Zerkalin, 10 mg/ml 30 ml

How to take, the dosage

Externally. The solution is applied to the affected area of pre-cleaned and dried skin twice a day, morning and evening.

Course of treatment: to obtain satisfactory results the treatment should be continued for 6-8 weeks, and if necessary it can be continued up to 6 months.

If after the treatment no improvement or new symptoms occur it is necessary to consult the physician.

Only use the drug according to the way of application and in such doses as specified in the instructions. If necessary, please consult your doctor before using the drug.

Interaction

The simultaneous use of clindamycin with other acne medications containing exfoliating, emollient and abrasive substances (e.g., benzoyl peroxide, tretinoin, resorcinol, salicylic acid, sulfur) is not recommended because of possible skin irritation.

There is cross-resistance of microorganisms to clindamycin and lincomycin. Antagonism between clindamycin and erythromycin has been noted.

Clindamycin has been found to disrupt neuromuscular transmission when used systemically and therefore may potentiate the effects of other peripheral myorelaxants, so even though blood levels are significantly lower after external administration of Zerkalin® than after oral clindamycin, the drug should be used with caution in patients receiving this group of drugs.

Special Instructions

Avoid contact of the drug with the mucous membranes of the eyes and mouth. After applying the drug you should wash your hands thoroughly. In case of accidental contact with sensitive surfaces (eyes, skin abrasions, mucous membranes) the area should be rinsed copiously with cool water.

The use of clindamycin (as well as other antibiotics) orally or parenterally in some cases is associated with the development of severe diarrhea and pseudomembranous colitis. Cases of diarrhea and colitis are rare when clindamycin is used topically, however, caution should be exercised and if severe or prolonged diarrhea develops, the drug should be discontinued and appropriate diagnostic and treatment measures taken if necessary.

If necessary, please consult a physician before using the drug.

Impact on ability to drive vehicles, machines

The drug Zerkalin® does not affect the ability to drive vehicles or engage in other potentially hazardous activities requiring increased concentration and quick psychomotor reaction.

Contraindications

• ulcerative colitis (including history);
• pseudomembranous colitis (including history
• pseudomembranous colitis (including history);
• Cron’s disease;
• high sensitivity to clindamycin or lincomycin or other components of Zerkalin in history;

With caution: Under 12 years of age, period of lactation, in patients with allergies, and in concomitant administration of muscle relaxants.

Side effects

Classification of adverse reactions by organ and organ system with indication of frequency of occurrence: Very common (≥1/10), common (≥1/100, < 1/10), infrequent (≥1/1000, < 1/100), rare (≥1/10000, < 1/1000), very rare (< 1/10000), including individual reports, frequency unknown (frequency cannot be estimated from available data).

Skin and subcutaneous tissue disorders

Very common: dry skin, skin irritation, urticaria

Frequent: seborrhea

Frequent unknown: contact dermatitis.

Gastrointestinal disorders

Infrequent: digestive disorders

Frequent unknown: Pseudomembranous colitis, abdominal pain

Infectious and parasitic diseases

Frequent unknown: folliculitis.

Visual disorders

Prevalence unknown: eye pain.

If any of the side effects listed in the instructions worsen or other side effects not listed in the instructions are noted, you should tell your doctor immediately.

Overdose

When applied externally clindamycin may be absorbed in amounts that cause systemic effects.

Possible systemic side effects include diarrhea, hemorrhagic diarrhea, including pseudomembranous colitis.

In case of overdose symptomatic and supportive therapy is indicated.

Similarities

Dalacin, Clindamycin, Clindavit